DiamiR Announces Formation of Advisory Board

MONMOUTH JUNCTION, NJ--(Marketwired - January 07, 2016) - DiamiR Biosciences, a developer of innovative minimally invasive diagnostic tests for early detection and monitoring of neurodegenerative diseases based on analysis of brain-enriched microRNA pairs in plasma, announced today the formation of its Advisory Board with three members: Dr. Mikhail Denissenko, Dr. Kevin Krenitsky, and Dr. Laura Philips.

Dr. Kira Sheinerman, CEO of DiamiR, noted, "As DiamiR's technology matures and we enter the product development stage, we will greatly benefit from the strategic guidance of leading diagnostic and life sciences experts joining our Advisory Board as founding members. We look forward to working with Laura, Kevin and Mikhail and welcome them to the company. We will continue attracting world-class experts with the range of expertise and knowledge in the healthcare industry to assure DiamiR is well equipped to advance its business objectives."

Dr. Denissenko has extensive experience in developing diagnostics and therapeutics, most recently as Director of New Product Portfolio Management at Prometheus Labs, a Nestle Health Science Company, and previously at Thermo Fischer Scientific. Dr. Denissenko is an experienced life sciences entrepreneur and has deep hands-on understanding of the product development process.

Dr. Krenitsky has over 15 years of experience establishing and managing diagnostic and biotech operations, most recently in the role of President of OpGen, Inc., and prior to that Chief Operating Officer, Chief Commercial Officer & SVP of International Strategy at Foundation Medicine, Inc. Dr. Krenitsky has strong expertise in developing and launching FDA-approved esoteric tests as well as novel laboratory developed tests.

Dr. Philips brings to DiamiR a wealth of experience and expertise in strategic and business development. Dr. Philips is the co-founder, President and Chief Executive Officer of Spheryx, Inc.; previously, she worked in a variety of top executive positions at growth biotech companies, served as a policy advisor to government officials, and was on the Faculty of Cornell University.

About DiamiR

DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's and Parkinson's diseases, and other conditions. The proprietary technology is based on quantitative analysis of organ-enriched microRNA signatures in plasma and is being developed for screening, patient stratification as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic and clinical centers and disease foundations. For more information, please visit the company's website at www.diamirbio.com.

Please Note : This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.

Contact Information:

Kira Sheinerman, PhD